Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

PLoS One. 2019 Jan 4;14(1):e0210593. doi: 10.1371/journal.pone.0210593. eCollection 2019.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0164646.].

Publication types

  • Published Erratum